These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19707525)

  • 1. Serum Abeta levels as predictors of conversion to mild cognitive impairment/Alzheimer disease in an ADAPT subcohort.
    Abdullah L; Luis C; Paris D; Mouzon B; Ait-Ghezala G; Keegan AP; Wang D; Crawford F; Mullan M
    Mol Med; 2009; 15(11-12):432-7. PubMed ID: 19707525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study.
    Sundelöf J; Giedraitis V; Irizarry MC; Sundström J; Ingelsson E; Rönnemaa E; Arnlöv J; Gunnarsson MD; Hyman BT; Basun H; Ingelsson M; Lannfelt L; Kilander L
    Arch Neurol; 2008 Feb; 65(2):256-63. PubMed ID: 18268197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High serum Abeta and vascular risk factors in first-degree relatives of Alzheimer's disease patients.
    Abdullah L; Luis C; Paris D; Ait-ghezala G; Mouzon B; Allen E; Parrish J; Mullan MA; Ferguson S; Wood M; Crawford F; Mullan M
    Mol Med; 2009; 15(3-4):95-100. PubMed ID: 19081767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of plasma Aβ as predictor of Alzheimer's disease in older individuals without dementia: a population-based study.
    Hansson O; Stomrud E; Vanmechelen E; Östling S; Gustafson DR; Zetterberg H; Blennow K; Skoog I
    J Alzheimers Dis; 2012; 28(1):231-8. PubMed ID: 21955816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline.
    Stockmann J; Verberk IMW; Timmesfeld N; Denz R; Budde B; Lange-Leifhelm J; Scheltens P; van der Flier WM; Nabers A; Teunissen CE; Gerwert K
    Alzheimers Res Ther; 2020 Dec; 12(1):169. PubMed ID: 33357241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.
    Fei M; Jianghua W; Rujuan M; Wei Z; Qian W
    J Neurol Sci; 2011 Jun; 305(1-2):92-6. PubMed ID: 21440911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum Tau-A and Tau-C Levels and Their Association with Cognitive Impairment and Dementia Progression in a Memory Clinic Derived Cohort.
    Axelsen TM; Høgh P; Bihlet AR; Karsdal MA; Henriksen K; Hasselbalch SG; Simonsen AH
    J Prev Alzheimers Dis; 2024; 11(3):730-738. PubMed ID: 38706289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased prediction value of biomarker combinations for the conversion of mild cognitive impairment to Alzheimer's dementia.
    Zhao A; Li Y; Yan Y; Qiu Y; Li B; Xu W; Wang Y; Liu J; Deng Y
    Transl Neurodegener; 2020 Aug; 9(1):30. PubMed ID: 32741361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer's disease.
    Sagare AP; Deane R; Zetterberg H; Wallin A; Blennow K; Zlokovic BV
    J Alzheimers Dis; 2011; 24(1):25-34. PubMed ID: 21157031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.
    Hansson O; Zetterberg H; Vanmechelen E; Vanderstichele H; Andreasson U; Londos E; Wallin A; Minthon L; Blennow K
    Neurobiol Aging; 2010 Mar; 31(3):357-67. PubMed ID: 18486992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.
    Graff-Radford NR; Crook JE; Lucas J; Boeve BF; Knopman DS; Ivnik RJ; Smith GE; Younkin LH; Petersen RC; Younkin SG
    Arch Neurol; 2007 Mar; 64(3):354-62. PubMed ID: 17353377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The free plasma amyloid Aβ
    Schraen-Maschke S; Duhamel A; Vidal JS; Ramdane N; Vaudran L; Dussart C; Buée L; Sablonnière B; Delaby C; Allinquant B; Gabelle A; Bombois S; Lehmann S; Hanon O;
    Neurobiol Dis; 2024 Apr; 193():106459. PubMed ID: 38423192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Ukoumunne O; Ladds EC; Martin S
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD010803. PubMed ID: 28328043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
    Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
    JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Olfactory Dysfunction and Amnestic Mild Cognitive Impairment and Alzheimer Disease Dementia.
    Roberts RO; Christianson TJ; Kremers WK; Mielke MM; Machulda MM; Vassilaki M; Alhurani RE; Geda YE; Knopman DS; Petersen RC
    JAMA Neurol; 2016 Jan; 73(1):93-101. PubMed ID: 26569387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol, copper and Abeta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT).
    Sparks DL; Petanceska S; Sabbagh M; Connor D; Soares H; Adler C; Lopez J; Ziolkowski C; Lochhead J; Browne P
    Curr Alzheimer Res; 2005 Dec; 2(5):527-39. PubMed ID: 16375656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
    Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
    Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A New Serum Biomarker Set to Detect Mild Cognitive Impairment and Alzheimer's Disease by Peptidome Technology.
    Abe K; Shang J; Shi X; Yamashita T; Hishikawa N; Takemoto M; Morihara R; Nakano Y; Ohta Y; Deguchi K; Ikeda M; Ikeda Y; Okamoto K; Shoji M; Takatama M; Kojo M; Kuroda T; Ono K; Kimura N; Matsubara E; Osakada Y; Wakutani Y; Takao Y; Higashi Y; Asada K; Senga T; Lee LJ; Tanaka K
    J Alzheimers Dis; 2020; 73(1):217-227. PubMed ID: 31771070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Midlife blood pressure, plasma β-amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study.
    Shah NS; Vidal JS; Masaki K; Petrovitch H; Ross GW; Tilley C; DeMattos RB; Tracy RP; White LR; Launer LJ
    Hypertension; 2012 Apr; 59(4):780-6. PubMed ID: 22392902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
    Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
    J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.